Daiichi Sankyo

News
daiichi sankyo

Lixiana hits the mark in catheter ablation trial

Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its gro